🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Besides his amazing insights on career and research, Prof. Syed A Hussain is a fabulous human being who continues to inspire Turkish young oncologists. Yüksel Ürün Emre Yekedüz Furkan Ceylan Hatice Bölek

We’ve just kicked off! A fulfilling kind of exhaustion after going through all the GU posters — learning the art of critical thinking from our amazing IDEA mentor, Dr. Ali Khaki . Grateful for the insights and inspiration! 💡Conquer Cancer, the ASCO Foundation #ASCO25 #GUonc #MentorshipMatters

Congrats Koray & Hacettepe team on this elegant work at #ASCO25 Taha Koray Sahin Albumin-myosteatosis gauge (AMG): a new body composition biomarker to predict survival in ICI-treated patients. Low AMG = worse PFS & OS Hacettepe Üniversitesi #Oncology @oncoalert ASCO Emre Yekedüz

Yüksel Ürün OncoAlert ASCO Laurence Albiges Deborah Mukherji André P. Fay Was so lovely to see you and your prolific team under your mentorship

Thank you Petros for the wonderful Greek dinner—felt just like home! And sharing the evening with dear Maha Hussain made it even more special. Grateful for the food, the laughter, and the company. 🇬🇷💙🇹🇷 Ευχαριστώ Petros Grivas Emre Yekedüz Hatice Bölek Enes Erul MD ASCO #ASCO25

Fantastic Greek dinner experience (11-year tradition) with numerous great friends/colleagues! Thanks Vivek Subbiah, MD for capturing the moment of “baklava consensus” with my friend Yüksel Ürün :Greek with walnut, Turkish with pistachios! Neeraj Agarwal, MD, FASCO George Pentheroudakis Dimitrios (Dimitri) Makrakis

Thank you EORTC for this insightful and informative statistics course! Your courses are always helpful for early-career researchers ☺️

Meta-analysis of 343 transplant recipients w/ advanced cancer treated w/ immune checkpoint inhibitors: 🟰53% cancer deaths at 3 yrs 🟰1-yr survival: 57% (cutaneous SCC), 48% (melanoma), 27% (other solid cancers) 🟰36% acute rejection, 18% graft loss ✅Steroids + mTOR inhibitors

PEACE-3: Enzalutamide + Radium-223 improved rPFS (19.4 vs 16.4 mo) and OS (42.3 vs 35.0 mo) in mCRPC with bone mets. ⚠️Fracture risk ⬆️ BUT mandatory bone-targeting agents ⬇️ it. tombal silke gillessen Advanced Prostate Cancer Consensus Conference ESMO - Eur. Oncology Annals of Oncology OncoAlert

Grateful to this amazing team for their consistent and collaborative efforts. Honored to be part of the 🇹🇷Turkish Kidney Cancer Consortium (TKCC). Let’s keep working, growing, and publishing together! 🧠🧬 OncoAlert Ankara Üniversitesi Oncology Brothers KidneyCAN IKCC Kidney Cancer Kidney Cancer

📢Latest study from the Turkish Oncology Group Kidney Cancer Consortium just published! Grateful to all collaborators for their valuable contributions! The Oncologist Serhat Sekmek Uzm Dr Saadet Sim Yüksel Ürün deniztural #kidneycancer #Immunotherapy

The Impact of Smoking on Nivolumab Outcomes in Renal Cell Carcinoma: Real-World Data from the Turkish Oncology Group #KidneyCancer Consortium academic.oup.com/oncolo/advance… This retrospective study from the Turkish Oncology Group Kidney Cancer Consortium found that current smoking

"“Kidney cancer is at a pivotal turning point, with new long-term data and novel therapies shaping the future of care.” -EMRE YEKEDÜZ, MD, AND YÜKSEL ÜRÜN, MD" ascopost.com/news/june-2025… via @ascopost Emre Yekedüz

📌Our new study from the Turkish Oncology Group Kidney Cancer Consortium just published! 📌Uric acid level is prognostic factor for OS in patients with mRCC treated with Nivolumab Yüksel Ürün Emre Yekedüz Hatice Bölek

Congrats Serhat Sekmek 🎉 Proud to be part of TKCC! 🇹🇷

Happy to share our insights in this invited commentary published in "Kidney Cancer" Huge congrats our rising ⭐️⭐️⭐️ fellow Hatice Bölek from Ankara Üniversitesi ! ⁉️Immunotherapy re-challenge appears to have limited efficacy in kidney cancer. What might be the underlying reasons from

Very important, clinically relevant question! Why does ICI re-challenge show limited benefit in metastatic kidney cancer? Is it the tumor microenvironment? Immune exhaustion? Or our sequencing strategies? OncoAlert KidneyCAN IKCC Kidney Cancer Ankara Üniversitesi Tıp Fakültesi

🧠 New commentary on ICI rechallenge in metastatic RCC highlights limited efficacy. journals.sagepub.com/doi/10.1177/24… 📉 OMNIVORE, GU16-260, TITAN-RCC: minimal benefit ✅ KEYNOTE-146: 56% ORR (pembro + lenva) ❌ CONTACT-03 & TiNivo-2: no OS/PFS gain vs VEGF TKI Before rechallenging the

🚨 New study alert! 🧪 In our multicenter study of mCRPC patients, we evaluated the impact of enzalutamide vs. abiraterone acetate in the immediately preceding line before ¹⁷⁷Lu-PSMA-617 therapy. 📊 Striking difference in overall survival: ✨ 12.8 months with prior